Crescent Biopharma, Inc. CBIO
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +13.66%
- 1 year
- +7.75%
- Open
- 13.94
- Prev close
- 14.07
- Mkt cap
- 500.74M
- Vol
- 189.52K
- Avg vol
- 348.98K
- EPS
- -7.63
- P/E
- 0.00
- Div yield
- 792.92%
More statistics
- Low
- 13.31
- High
- 14.57
- Forward P/E
- -17.04
- Beta
- 1.29
- Short ratio
- 0.19
- Inst. own
- 8.75%
- Dividend
- 15.94
- Ex-div date
- Jan 12, 2023
- Earnings
- Oct 26, 2023
- 50-d avg
- 0.638078
- 200-d avg
- 0.365086
- 1y target
- 0.00
5D chart
Signals (106)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 1:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:45 AM | 2 days ago |
| RSI: Overbought | Oct 29, 11:05 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:45 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 3 days ago |
| RSI: Oversold | Oct 28, 9:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 4 days ago |
| RSI: Oversold | Oct 27, 1:55 PM | 4 days ago |
| RSI: Oversold | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 11:35 AM | 4 days ago |
| RSI: Overbought | Oct 27, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:25 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 26, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:20 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 26, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 23, 3:55 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:25 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 3:25 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:15 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:05 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:00 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:50 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:50 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:20 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:50 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 12:50 PM | 1 week ago |
| SMA: Bullish | Oct 23, 11:40 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:00 AM | 1 week ago |
| SMA: Bullish | Oct 23, 10:35 AM | 1 week ago |
News
-
1 week ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $36 price target.
-
2 weeks ago benzinga.com
Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027
Global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC, on track to commence dosing this quarter; initial data expected in the second half 2027Phase 1/2 trial of CR-003 (SKB105), an…
-
3 weeks ago benzinga.com
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.
-
3 weeks ago benzinga.com
Crescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid Tumors
Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today…
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock…
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target
Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
-
2 months ago benzinga.com
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target
Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
-
3 months ago benzinga.com
Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.79) by 6.33 percent. This is a 84.99 percent increase over losses of…
-
3 months ago benzinga.com
Crescent Biopharma Commences Offering Of Common Stock, Pre-Funded Warrants; Terms Undisclosed
Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today…
5 months ago benzinga.com
This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.
-
5 months ago benzinga.com
Crescent Biopharma Announces Trial In Progress Presentation For ASCEND Study Of CR-001, At ASCO 2026 Annual Meeting; Multiple CR-001 Clinical Data Readouts Anticipated Beginning In Q1 2027
Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today…
6 months ago benzinga.com
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results
Stocks traded mixed, with Dow down 0.1% but NASDAQ up 1.06%. Chevron reported mixed Q1 results. Esperion, Five9, Atlassian soared while Summit, Crescent, LendingTree fell.
6 months ago benzinga.com
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue
US stocks traded higher, with the Nasdaq up 1%. Dow up 0.05%, Nasdaq up 1.13%, S&P 500 up 0.58%. Tech shares jumped 1.6%, energy stocks fell 1.5%.
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
6 months ago benzinga.com
Crescent Biopharma Q1 EPS $(0.70) Beats $(0.98) Estimate, Sales $1.039M Beat $357.143K Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.98) by 28.57 percent. This is a 96.43 percent increase over losses of…
6 months ago benzinga.com
ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock
6 months ago benzinga.com
ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock
-
7 months ago benzinga.com
Crescent Biopharma Files Prospectus For Resale Of Up To ~19.7M Shares By Selling Securityholders From Private Placement And Warrants
This prospectus relates to the proposed resale or other disposition by the selling securityholders identified herein (the "Selling Securityholders") of up to (i) 13,664,251 (the "Private Placement…
-
8 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and lowers the price target from $25 to $22.
-
8 months ago benzinga.com
Crescent Biopharma Q4 EPS $(4.01) Misses $(2.31) Estimate, Sales $10.844M Beat $4.000M Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(4.01) per share which missed the analyst consensus estimate of $(2.31) by 73.44 percent. This is a 79.69 percent increase over losses…
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
9 months ago benzinga.com
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
-
9 months ago benzinga.com
Guggenheim Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $35
Guggenheim analyst Brad Canino initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $35.
-
10 months ago benzinga.com
Crescent Biopharma Announces Regulatory Clearances Of IND Applications For CR-001, PD-1 X VEGF Bispecific Antibody, And CR-003, ITGB6-Targeted ADC, For Treatment Of Advanced Solid Tumors
CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with…
11 months ago benzinga.com
What's Happening With Crescent Biopharma Stock Today?
Cresent Biopharma shares were trading higher Thursday but have since reversed and begun trading lower after the company announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical.
-
11 months ago benzinga.com
Market-Moving News for December 4th
PATH: 15% | UiPath shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 sales guidance with its midpoint above estimates. SNOW: -9% | Snowflake
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
11 months ago benzinga.com
Crescent Biopharma Secures $185M Private Placement; Investors To Purchase 13.8M Ordinary Shares At $13.41 Or Pre-Funded Warrants At $13.409
Private Placement FinancingCrescent also announced today that it entered into a securities purchase agreement for a private investment of securities to institutional and other accredited investors…
-
11 months ago benzinga.com
Sichuan Kelun-Biotech And Crescent Biopharma Partner To Develop, Commercialize Oncology Therapeutics; Cos To Advance CR-001, PD-1 x VEGF Bispecific Antibody, And SKB105 In Global Markets And China
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and ChinaCollaboration designed to accelerate…
-
12 months ago benzinga.com
Crescent Biopharma Q3 EPS $(1.27) Beats $(1.98) Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.98) by 35.92 percent.
-
12 months ago benzinga.com
Crescent Biopharma To Present Preclinical Data From CR-001 Antibody For Solid Tumor Tumors At Society For Immunotherapy Of Cancer
Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that…
1 year ago benzinga.com
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago benzinga.com
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago benzinga.com
US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity
U.S. futures were higher on Wednesday as oil futures tumbled after Donald Trump called for an "Unconditional Surrender" by Iran late Tuesday.
1 year ago benzinga.com
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
3 years ago benzinga.com
Why Titan International Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) shares jumped 153% to $3.24 after the company announced the launch of PrecisionCHD, an integrated epigenetic-genetic blood test for the early…
-
4 years ago benzinga.com
20 Stocks Moving in Friday's Pre-Market Session
Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 115 companies reached new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning, 136 companies reached new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning, 282 companies set new 52-week lows.